Planned maintenance may cause outages to the Department of Health and Aged Care’s network from 5:15 pm AEDT on 30 November to 10:00 pm AEDT on 1 December 2024. Access to TGA databases such as TBS Portal, ARTG and DAEN may be affected. We apologise for any inconvenience.
BAVENCIO (Merck Healthcare Pty Ltd)
Product name
BAVENCIO
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
190 working days (255)
Active ingredients
avelumab
Registration type
EOI
Indication
BAVENCIO (concentrated solution for injection) in combination with axitinib is now also indicated for the first-line treatment of patients with advanced renal cell carcinoma (RCC).